Expression of angiogenesis-related microRNAs in serum samples of pacients with non-Hodgkin diffuse large B-cell lymphoma, at diagnosis and at the moment of recurrence

• Grant number: 14/10578-2
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: August 01, 2014
• End date: July 31, 2016
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Gisele Wally Braga Colleoni
• Grantee: Marcela Do Vale Elias
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
• Associated research grant: 10/17668-6 - Identification of biomarkers and possible therapeutical targets in B-cell lymphoproliferative disorders, AP.TEM

Abstract

The search for sensitive biomarkers for the early detection of neoplastic changes is a constant goal of cancer research. Thus, biomarkers that can be collected from body fluids, such as serum or plasma, are particularly desired, which increases the importance of studying the extracellular microRNAs present in the bloodstream. Specifically, in the case of Diffuse Large B Cell Lymphoma (DLBCL), the detection of cancer at an early stage appears to be crucial for reducing the mortality caused by this disease, and most deaths resulting from this type of lymphoma can be avoided by detection and treatment of cancer at an early stage or monitoring for recurrence. In a previous study by our group (Borges et al., 2013), we evaluated the expression of pro-and anti- angiomas in tissues affected by DLBCL embedded in paraffin. The microRNA profile of 101 cases of DLBCL admitted at the Hospital São Paulo between 2000 and 2010 was evaluated in this study. Pro-angiomiRs Let-7f, miR-130a, miR-210, miR-296 and miR-378 and anti-angiomiRs miR-16, miR-20b, miR-221, and miR-328 were selected for analysis and were considered differentially expressed when levels of tumor samples were 1.2 times higher or lower than in normal samples. Four angiomiRs emerged as potential new targets: pro-angiomiRs miR-296, miR-210, and miR-378, highly expressed in respectively 56.40%, 55.40%, and 48.50% of DLBCL cases and anti-angioma-20b, lowly expressed in 65.30% of cases. The present study aims, from these results, to evaluate the expression of these four microRNAs in the serum of patients with DLBCL, at diagnosis and at the moment of recurrence. (AU)